The expression of CB1 was identified as a positive prognostic factor for disease-free survival in patients with tongue cancer [64] but not prostate cancer [65], although prostate cancer cells, like other cancer cells, are killed by CB1 or CB2 agonists in vitro [25,66,67,68]. Here, CNR1 is linked to prostate carcinoma.